IJIMM, Volume 3, Issue 10, 2025 ISSN: 2995-5319
http://medicaljournals.eu/index.php/IJIMM/issue/view/3
INTERNATIONAL JOURNAL OF INTEGRATIVE AND MODERN MEDICINE

Prevalence, Pathogenesis, Diagnosis, and Treatment of Myocardial Infarction in Patients With Type 2 Diabetes Mellitus

Djurayeva Ra'no Xayrulloyevna
Department of Fundamental Medical Sciences of the Asian International University. Bukhara, Uzbekistan

Abstract: Type 2 diabetes mellitus (T2DM) significantly increases the risk of cardiovascular complications, particularly myocardial infarction (MI). Patients with T2DM are more likely to experience silent or atypical presentations of MI, leading to delayed diagnosis and worse outcomes. The pathogenesis involves chronic hyperglycemia-induced endothelial dysfunction, accelerated atherosclerosis, and pro-inflammatory states. Diagnostic approaches require a high index of suspicion and may include cardiac biomarkers, ECG, and imaging studies. Treatment strategies for MI in diabetic patients involve prompt revascularization, optimal glycemic control, and long-term use of antiplatelet agents, statins, ACE inhibitors, and beta-blockers. Early detection and individualized management are crucial to improving prognosis in this high-risk population.

Keywords: Type 2 Diabetes Mellitus, myocardial Infarction, cardiovascular risk, atherosclerosis, endothelial dysfunction, hyperglycemia

1. Myocardial Infarction and Type 2 Diabetes Mellitus (T2DM): Epidemiology and Risk

Incidence and Relative Risk

- Patients with type 2 diabetes mellitus have a **2–4 times higher risk** of developing cardiovascular diseases, particularly **myocardial infarction (MI)**, compared to the general population.
- Some sources report that the **risk of acute myocardial infarction is 6–10 times higher** in diabetic patients.
- The **mortality rate due to coronary heart disease** is also reported to be **2–4 times higher** among diabetic patients than in non-diabetic individuals.
- For instance, in a study conducted on a Chinese cohort, the incidence of **recurrent MI** in patients with T2DM was found to be **43.7 per 1000 patient-years**, compared to **25.1 per 1000 patient-years** in non-diabetic patients.
- Moreover, MI in patients with T2DM tends to have **more severe clinical outcomes and complications**, as diabetes exacerbates post-infarction damage and recovery.
- These numbers may vary by region and study methodology, but the general trend is clear: **type 2 diabetes significantly increases the risk of myocardial infarction**.

2. Etiology: Causes and Risk Factors

Key factors contributing to MI in patients with type 2 diabetes include:

1. Atherosclerosis and Atherogenic Effects

- In diabetes, the atherosclerotic process is accelerated due to **endothelial dysfunction** and increased accumulation of lipids and cholesterol in blood vessels.
- Impaired synthesis of vasodilatory agents, particularly **nitric oxide (NO)**, plays a major role in vascular dysfunction.
- **Dyslipidemia**, characterized by elevated levels of cholesterol, LDL, and triglycerides, further contributes to the development of atherosclerosis.

2. **Hyperglycemia and Glucotoxicity**

- Persistent **hyperglycemia** exerts a toxic effect on cells and promotes **oxidative stress** through the generation of free radicals.
- This leads to damage of **vascular cells**, including endothelial and smooth muscle cells.
- Hyperglycemia also induces metabolic disturbances such as **polyol pathway activation**, increased **endothelin** levels, and **advanced glycation end-products (AGEs)**, all of which contribute to vascular injury.

3. **Prothrombotic State and Thrombosis**

- Diabetes is associated with **increased platelet activity** and **coagulation abnormalities**, making the blood more prone to clot formation.
- In combination with vascular wall injury, the presence of atherosclerotic plaques, and disturbed blood flow, the risk of **thrombosis** is significantly elevated.

4. **Microvascular and Macrovascular Complications**

- Diabetes often leads to **microangiopathy**, damaging capillaries and arterioles, as well as **macrovascular complications** involving larger arteries such as the **coronary arteries**.
- These changes result in **reduced vascular elasticity**, **arterial wall thickening**, and **narrowing of the vessels**, all of which increase the risk of myocardial infarction.

5. **Hypertension (High Blood Pressure)**

- Many patients with type 2 diabetes mellitus (T2DM) also suffer from arterial hypertension. This condition increases myocardial infarction (MI) risk by inducing vascular wall stress, endothelial injury, vascular hypertrophy, and promoting atherosclerotic development.

6. **Obesity and Insulin Resistance**

- Most T2DM patients present with central (abdominal) obesity and insulin resistance. These conditions promote lipolysis, adverse lipid profiles, systemic inflammation, and atherogenesis.

7. **Inflammation and Oxidative Stress**

- Chronic inflammation associated with diabetes — including elevated cytokine levels and activation of monocytes and macrophages — may destabilize atherosclerotic plaques and contribute to thrombogenesis.

8. **Genetic Factors**

- For example, researchers in Uzbekistan have studied the T786C polymorphism of the **NOS3 gene** (encoding endothelial nitric oxide synthase) and its effect on endothelial function. These genetic and metabolic factors act synergistically: atherosclerotic changes, hyperglycemia, thrombogenesis, and micro/macrovascular damage reinforce each other, substantially increasing the risk of MI.

3. Pathogenesis (Pathophysiological Mechanisms)

- MI occurs due to sudden disruption of blood supply to a specific region of the myocardium, leading to cellular necrosis. In diabetic patients, the development of MI follows several key steps and modifications:

1. **Progressive Atherosclerotic Changes in Blood Vessels**

- The vessel wall becomes increasingly infiltrated with atheromatous plaques. In diabetes, these plaques tend to be more **unstable**, making them more likely to rupture and trigger thrombotic events.

2. **Plaque Rupture or Erosion**

- Plaque rupture exposes subendothelial materials to blood flow, promoting **platelet adhesion**, thrombus formation, and rapid luminal occlusion.

3. Thrombus Formation and Vascular Obstruction

- At the site of plaque rupture, a thrombus may form and occlude the coronary artery. The **prothrombotic state** in diabetic patients accelerates this process.

4. Ischemia and Necrosis

- When an artery is blocked, downstream tissue becomes ischemic due to lack of oxygen and nutrients. Prolonged ischemia leads to **irreversible necrosis** of myocardial cells.
- In diabetic patients, compensatory mechanisms (e.g., collateral circulation) may be insufficient due to **microvascular damage** and impaired vascular function, leading to larger ischemic zones.

5. Reperfusion Injury

- Restoration of blood flow (e.g., via PCI or thrombolysis) can cause **reperfusion injury**, characterized by oxidative stress, generation of reactive oxygen species (ROS), membrane damage, and **cell apoptosis**. These processes may be **exacerbated in diabetes**.

6. Extensive Damage and Ventricular Remodeling

- Post-MI, surviving myocardium undergoes **hypertrophy**, **matrix remodeling**, **fibrosis**, and **left ventricular remodeling**. In diabetic patients, this remodeling is often **more adverse**, increasing the risk of heart failure.

7. Microcirculatory Dysfunction

- Due to diabetic microangiopathy, **capillary-level perfusion may remain impaired**, even after restoring epicardial blood flow. This means tissue-level oxygen delivery remains inadequate, worsening outcomes.
- Thus, MI pathogenesis in diabetes is more complex than a simple arterial occlusion; it involves **plaque instability**, **thrombogenicity**, **vascular injury**, and **heightened sensitivity to reperfusion injury**.

4. Clinical Course, Delayed Complications, and Prognosis

- In diabetic patients, MI often **does not present with classical symptoms** such as chest pain or dyspnea. "**Silent MI**" or atypical presentations are more common, which may lead to **delayed diagnosis**.
- Post-MI complications such as **heart failure, arrhythmias, reinfarction**, and **post-infarction angina** are **more frequent and more severe** in patients with diabetes.
- For instance, in the aforementioned Chinese study, patients with T2DM had a **1.67 times higher risk** of recurrent MI and a **1.90 times higher risk** of all-cause mortality compared to non-diabetic patients.
- Gender differences exist: one study showed that **in-hospital mortality** and MI severity were **higher among women** with T2DM compared to men.
- Reperfusion procedures (such as PCI) may be **technically more challenging** in diabetic patients due to widespread **diffuse atherosclerosis** and complex coronary anatomy.
- **Post-MI ventricular remodeling** and **functional recovery** tend to be slower and less favorable in diabetic individuals.

5. Diagnosis and Monitoring

- MI diagnosis in diabetic patients follows standard protocols, including:
- Electrocardiography (ECG): ST-segment changes, pathologic Q waves

- Cardiac biomarkers: Troponin, CK-MB
- Echocardiography: To assess infarct size and left ventricular function
- Coronary angiography: To evaluate for PCI or CABG candidacy
- Laboratory tests: Lipid profile, blood glucose, HbA1c, natriuretic peptides (BNP), etc.
- In diabetic patients, additional tests are critical:
- Glucose control (fasting glucose, HbA1c)
- Renal function tests and electrolytes
- Screening for diabetic nephropathy, retinopathy, and other complications
- Glycemic fluctuations are common during MI and reperfusion periods; therefore, **tight glucose monitoring** is essential.

6. Therapeutic Approaches — General Principles and Diabetes-Specific Considerations

- Standard MI treatments (reperfusion therapy, antiplatelets, statins, ACE inhibitors, beta-blockers) apply to diabetic patients, but specific considerations must be accounted for:

6.1. Reperfusion Therapy

- **Primary PCI** is preferred when available; in diabetic patients, it **reduces mortality** more significantly.
- If PCI is unavailable, **thrombolytic therapy** (e.g., tPA) may be considered, though the **risk-benefit ratio must be carefully evaluated** due to coagulation abnormalities in diabetes.

6.2. Antiplatelet Therapy

- **Aspirin** and **P2Y12 inhibitors** (clopidogrel, prasugrel, ticagrelor) are essential for preventing recurrent events.
- Diabetic patients may require **more intensive antiplatelet therapy**, but bleeding risk must be balanced carefully.

6.3. Lipid-Lowering Therapy

- **Statins** are crucial post-MI to reduce LDL cholesterol and slow atherosclerosis.
- **New agents like PCSK9 inhibitors may offer additional benefits in high-risk diabetic patients.**
- **Strict lipid control** is a priority in diabetes management.

6.4. Hypertension Control

ACE inhibitors or **ARBs** provide cardioprotective effects post-MI.

- Blood pressure targets in diabetic patients are usually stricter (e.g., **<130/80 mmHg**).
- Other agents (beta-blockers, diuretics) may be used based on individual patient needs.

6.5. Glucose Control and Antidiabetic Therapy

- Glucose management in post-MI diabetic patients is critical.
- Some studies suggest **intensive glucose control** reduces cardiovascular risk, including MI (meta-analysis showed OR ≈ 0.90).
- However, **overtight glycemic control** may increase the risk of **hypoglycemia** and adverse outcomes.
- Glucose-lowering medications with **cardioprotective effects**, such as:
- **SGLT2 inhibitors**

- **GLP-1 receptor agonists** are increasingly recommended.
- **Insulin therapy** may be required during acute MI to control glucose levels, although some studies (e.g., BETonMACE) suggest a potential link between insulin use and increased cardiovascular events — warranting careful selection and monitoring.

6.6. Revascularization Strategy

- **Coronary artery bypass grafting (CABG)** is considered in multivessel disease.
- Studies suggest **improved outcomes** with revascularization (PCI or CABG) in diabetic patients versus medical therapy alone.
- The choice depends on:
- Coronary anatomy
- Disease severity
- Comorbid conditions (e.g., nephropathy)

6.7. Rehabilitation and Secondary Prevention

- **Lifestyle modifications:**
- Healthy diet (low fat, low cholesterol)
- Increased physical activity
- Weight reduction
- Smoking cessation
- **Control of cardiovascular risk factors:**
- Dyslipidemia, hypertension, obesity, and psychological stress
- **Cardiac rehabilitation programs** play a vital role in recovery and return to normal function.
- **Regular follow-up and monitoring** are essential:
- ECG, echocardiography
- HbA1c, renal function
- Lipid profile
- Assessment for micro- and macrovascular complications (e.g., nephropathy, retinopathy)

7. Conclusions and Recommendations

- Myocardial infarction is **significantly more prevalent** and has a **worse prognosis** in patients with type 2 diabetes.
- The pathogenesis involves multiple mechanisms:
- **Atherosclerosis**
- **Hyperglycemia**
- **Prothrombotic state**
- **Micro/macrovascular injury**
- **Inflammation and oxidative stress**
- Effective management requires not only standard MI treatments but also **comprehensive diabetes control**.

- Choosing antidiabetic agents with **cardiovascular benefit** (e.g., SGLT2 inhibitors, GLP-1 agonists) is crucial.
- Secondary **prevention**, **lifestyle interventions**, and **multidisciplinary follow-up** are key to improving long-term outcomes.